Company news

Alligator Bioscience AB news in 2026

Alligator Bioscience AB's news releases, calls and decks from 2026, newest first.

View company

Alligator Bioscience appoints Johan Giléus as CEO – Søren Bregenholt to step down at year-end

October 4, 2026

Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue

September 29, 2026

Alligator Bioscience announces final outcome in rights issue

September 22, 2026

Alligator Bioscience announces preliminary outcome in rights issue

September 21, 2026

Alligator Bioscience publishes prospectus in connection with rights issue

August 31, 2026

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

August 26, 2026

Invitation to Alligator Bioscience's Earnings Call on 26 August 2026

August 20, 2026

Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans

July 23, 2026

Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer

July 2, 2026

Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update

May 5, 2026

Invitation to Alligator Bioscience's Earnings Call on 5 May 2026

April 28, 2026

Alligator Bioscience Comments on Henlius Presentation of HLX49 Preclinical Data at AACR 2026

April 23, 2026

New Data from Investigator‑Initiated Study Evaluating Alligator Bioscience’s Mitazalimab to Be Presented at AACR Annual Meeting 2026

April 20, 2026

Alligator Bioscience provides an update on mitazalimab

April 13, 2026

Alligator Bioscience Provides an Update on Mitazalimab

April 10, 2026

Notice of Annual General Meeting in Alligator Bioscience AB

March 30, 2026

The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

March 27, 2026

Alligator Bioscience Publishes Annual Report for 2025

March 26, 2026

Alligator Bioscience AB announces outcome of exercise of warrants series TO 14

March 20, 2026

Management intends to subscribe pro rata in Alligator Bioscience’s warrant program TO 14

March 16, 2026

Alligator Bioscience Strengthens Intellectual Property Protection for Bispecific Antibody Platform

March 10, 2026

Alligator Bioscience Comments on Henlius Dosing First Patient in Phase 2/3 Breast Cancer Study of HLX22

March 2, 2026

Exercise Price Determined for the Exercise of Warrants Series TO 14 in Alligator Bioscience AB

February 27, 2026

Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update

February 12, 2026

Invitation to Alligator Bioscience's Earnings Call on 12 February 2026

February 5, 2026

Change in Number of Shares and Votes in Alligator Bioscience AB

January 30, 2026

Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

January 9, 2026

Calls in 2026

Decks in 2026